SUN-LB064 A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia | Zendy

Kyriakie Sarafoglou | Zendy; Ron S. Newfield | Zendy; Maria G. Vogiatzi | Zendy; Erik A. Imel | Zendy; A. Ola Odugbesan | Zendy; Ivy-Joan Madu | Zendy; Samer Nakhle | Zendy; Alexis Howerton | Zendy; Michael Huang | Zendy; Kelly Vandever | Zendy; Rong Lin | Zendy; Alyssa Wu-Zhang | Zendy; Richard J. Auchus | Zendy

Open Access

SUN-LB064 A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia

Author(s) -

Kyriakie Sarafoglou,

Ron S. Newfield,

Maria G. Vogiatzi,

Erik A. Imel,

A. Ola Odugbesan,

Ivy-Joan Madu,

Samer Nakhle,

Alexis Howerton,

Michael Huang,

Kelly Vandever,

Rong Lin,

Alyssa Wu-Zhang,

Richard J. Auchus

Publication year - 2019

Publication title -

journal of the endocrine society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.046

H-Index - 20

ISSN - 2472-1972

DOI - 10.1210/js.2019-sun-lb064

Subject(s) - congenital adrenal hyperplasia , medicine , cohort , adverse effect , androgen , endocrinology , adrenocorticotropic hormone , regimen , pharmacodynamics , dosing , glucocorticoid , androgen excess , pharmacokinetics , gastroenterology , hormone , insulin resistance , polycystic ovary , insulin

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research